Pfizer Current Ratio 2010-2023 | PFE
Current and historical current ratio for Pfizer (PFE) from 2010 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Pfizer current ratio for the three months ending December 31, 2023 was 0.91.
| Pfizer Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-12-31 |
$43.33B |
$47.79B |
0.91 |
| 2023-09-30 |
$74.01B |
$31.14B |
2.38 |
| 2023-06-30 |
$73.35B |
$34.65B |
2.12 |
| 2023-03-31 |
$50.08B |
$36.56B |
1.37 |
| 2022-12-31 |
$51.26B |
$42.14B |
1.22 |
| 2022-09-30 |
$70.40B |
$44.31B |
1.59 |
| 2022-06-30 |
$67.47B |
$47.41B |
1.42 |
| 2022-03-31 |
$54.42B |
$39.27B |
1.39 |
| 2021-12-31 |
$59.69B |
$42.67B |
1.40 |
| 2021-09-30 |
$57.90B |
$41.80B |
1.39 |
| 2021-06-30 |
$48.81B |
$35.66B |
1.37 |
| 2021-03-31 |
$39.53B |
$26.65B |
1.48 |
| 2020-12-31 |
$35.07B |
$25.92B |
1.35 |
| 2020-09-30 |
$47.74B |
$34.15B |
1.40 |
| 2020-06-30 |
$46.42B |
$32.72B |
1.42 |
| 2020-03-31 |
$34.74B |
$33.89B |
1.03 |
| 2019-12-31 |
$32.80B |
$37.30B |
0.88 |
| 2019-09-30 |
$33.46B |
$36.97B |
0.91 |
| 2019-06-30 |
$47.07B |
$32.03B |
1.47 |
| 2019-03-31 |
$45.29B |
$29.42B |
1.54 |
| 2018-12-31 |
$49.93B |
$31.86B |
1.57 |
| 2018-09-30 |
$41.58B |
$29.01B |
1.43 |
| 2018-06-30 |
$37.30B |
$32.16B |
1.16 |
| 2018-03-31 |
$34.84B |
$27.37B |
1.27 |
| 2017-12-31 |
$41.14B |
$30.43B |
1.35 |
| 2017-09-30 |
$40.29B |
$28.22B |
1.43 |
| 2017-06-30 |
$36.39B |
$27.18B |
1.34 |
| 2017-03-31 |
$35.88B |
$24.86B |
1.44 |
| 2016-12-31 |
$38.95B |
$31.12B |
1.25 |
| 2016-09-30 |
$38.50B |
$34.76B |
1.11 |
| 2016-06-30 |
$43.85B |
$32.10B |
1.37 |
| 2016-03-31 |
$41.30B |
$28.74B |
1.44 |
| 2015-12-31 |
$43.80B |
$29.40B |
1.49 |
| 2015-09-30 |
$45.00B |
$27.85B |
1.62 |
| 2015-06-30 |
$51.72B |
$24.14B |
2.14 |
| 2015-03-31 |
$49.44B |
$20.22B |
2.45 |
| 2014-12-31 |
$55.60B |
$21.59B |
2.58 |
| 2014-09-30 |
$56.99B |
$19.92B |
2.86 |
| 2014-06-30 |
$58.29B |
$21.94B |
2.66 |
| 2014-03-31 |
$57.79B |
$24.79B |
2.33 |
| 2013-12-31 |
$56.24B |
$23.37B |
2.41 |
| 2013-09-30 |
$59.50B |
$20.37B |
2.92 |
| 2013-06-30 |
$61.44B |
$23.45B |
2.62 |
| 2013-03-31 |
$64.76B |
$27.54B |
2.35 |
| 2012-12-31 |
$64.83B |
$29.19B |
2.22 |
| 2012-09-30 |
$57.13B |
$29.13B |
1.96 |
| 2012-06-30 |
$58.77B |
$30.80B |
1.91 |
| 2012-03-31 |
$54.86B |
$27.09B |
2.03 |
| 2011-12-31 |
$60.82B |
$28.91B |
2.10 |
| 2011-09-30 |
$62.73B |
$27.86B |
2.25 |
| 2011-06-30 |
$60.48B |
$30.47B |
1.99 |
| 2011-03-31 |
$58.24B |
$29.17B |
2.00 |
| 2010-12-31 |
$61.01B |
$28.64B |
2.13 |
| 2010-09-30 |
$54.09B |
$24.17B |
2.24 |
| 2010-06-30 |
$51.10B |
$24.68B |
2.07 |
| 2010-03-31 |
$49.92B |
$25.92B |
1.93 |
| 2009-12-31 |
$61.67B |
$37.23B |
1.66 |
| 2009-09-30 |
$73.78B |
$23.99B |
3.08 |
| 2009-06-30 |
$71.55B |
$26.11B |
2.74 |
| 2009-03-31 |
$54.25B |
$23.34B |
2.32 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$149.038B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
